Vascular access site complication: Which Medications Cause It? (213 Reports Across 7 Drugs)
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Vascular access site complication has been reported as an adverse event with 7 different drugs in the FDA's FAERS database, with 213 total reports. 2 of these reports resulted in death.The drugs most commonly associated with Vascular access site complication are CONESTAT ALFA, HUMAN C1-ESTERASE INHIBITOR, and PEMBROLIZUMAB.
213
Total Reports
7
Drugs Involved
2
Deaths
39
Hospitalizations
51.2 yrs
Average Patient Age
75.0% / 25.0%
Female / Male
Which Drugs Cause Vascular access site complication Most Often?
| Drug | Reports | % of Drug Reports | Deaths | Hosp. | Life-Threat. |
|---|---|---|---|---|---|
| CONESTAT ALFA | 90 | 6.0% | 0 | 5 | 0 |
| HUMAN C1-ESTERASE INHIBITOR | 74 | 0.5% | 1 | 14 | 0 |
| PEMBROLIZUMAB | 14 | 0.0% | 0 | 2 | 0 |
| CARBOPLATIN | 8 | 0.0% | 1 | 0 | 0 |
| PEMETREXED | 7 | 0.0% | 0 | 0 | 0 |
| ASPIRIN | 5 | 0.0% | 0 | 5 | 0 |
| CLOPIDOGREL BISULFATE | 5 | 0.0% | 0 | 5 | 0 |